Search

everythinglearnresearchcommunity

for

Search:↓

Researchers found new potential treatments for conditions related to the androgen receptor, like male hormonal contraception, by testing thousands of compounds.

The new compounds moderately block a specific enzyme and strongly counteract a male hormone, suggesting potential for treating certain male-related health conditions.

Flutamide, an antiandrogen, has minimal impact on female rat endocrine systems and does not significantly change their reproductive cycles.

Flutamide and finasteride reduced sex hormones in pregnant hyenas, but increased them in males.

Antiandrogens and androgen inhibitors like spironolactone, finasteride, and dutasteride can treat hair loss and skin conditions, but they have risks and side effects, including potential harm to pregnant women and risks of cancer and heart issues. Herbal remedies also have antiandrogenic effects but lack safety validation.

A new, less toxic and more efficient method to create the anti-baldness compound RU58841 was developed in 2014.

The enzyme steroid sulfatase is linked to breast cancer and other conditions, and inhibitors are being developed for treatment.

Some newly made compounds are promising for treating enlarged prostate, hair loss, viruses, and prostate cancer, and might be better than current drugs.

Lack or blocking of SRD5a, a key component in hormone creation, can lead to conditions like pseudohermaphrodism and affect hair growth, bone mass, muscle strength, and reproductive health. More research is needed on its regulation from fertilization to adulthood.

New treatments for enlarged prostate are being developed, some of which may be more effective than current medications.

Oral antiandrogens effectively treat female hair loss, with better results in higher hair loss grades.

Flutamide effectively reduced excessive hair growth and improved related symptoms in hirsutism patients without significant side effects.

Finasteride, CPA, and flutamide are all equally effective in reducing excessive hair growth in women.

Anti-acne medications may work by reducing the activity of a protein involved in acne development.

Steroid sex hormones activate matriptase in prostate cancer cells but not in breast cancer cells.

Low doses of mixed chemicals cause permanent reproductive malformations in male rats.

Some herbs show promise as antiandrogenic agents.

Spironolactone is better than placebo for reducing excessive hair growth in women, but its effectiveness for acne is unclear due to small study sizes.

Taking spironolactone and linestrenol for androgen excess can lead to lower bone density in young women.

Flutamide, dutasteride, and finasteride dissolve differently in supercritical carbon dioxide, with dutasteride dissolving the least.

Using two drugs together, Flutamide and 4-MA, is more effective for blocking male hormones than using each one alone.

Certain adrenal hormones can strongly stimulate oil gland growth in hamster skin, similar to male hormones.

Topical therapies show promise for hair loss and acne treatment with minimal side effects.

Low testosterone may increase COVID-19 severity in men.

Prostate cancer cells can make their own androgens to activate the androgen receptor, and treatments like abiraterone may increase this ability, suggesting new therapies should target the entire steroid-making pathway.

Metformin is effective for treating excessive hair growth in women with PCOS and may work better than the standard treatment in some ways.

11α-Hydroxyprogesterone is changed into different substances by certain enzymes and may play a role in prostate cancer.

The method accurately measures steroid hormones in hair to study hormone dynamics related to hair loss.

Selective non-steroidal inhibitors of 5α-reductase type 1 can help treat DHT-related disorders.

Certain inhibitors can potentially treat prostate cancer and other hormone-dependent conditions by controlling sex hormone levels in cells.